COGT
Cogent Biosciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Cogent Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Feb 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
−2.03%
vs ±9.6% implied · ×0.21
shaded = implied · ▲▼ = realized
Cogent Biosciences, Inc.
31.00
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Cogent Biosciences, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Cogent Biosciences, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
Expected move
Inputsspot 31.02exp Nov 20ATM strike 31ATM straddle 4.68IV 79%
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $993.9M | 13.15% | +11.06% |
| BlackRockindex-like | $671.5M | 8.89% | +8.15% |
| Vanguard Portfolioindex-like | $312.4M | 4.13% | +10.08% |
| Vanguardindex-like | $286.9M | 3.80% | +7.50% |
| State Streetindex-like | $269.5M | 3.57% | +22.98% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $993.9M | 13.15% | +11.06% |
| BlackRockindex-like | $671.5M | 8.89% | +8.15% |
| Vanguard Portfolioindex-like | $312.4M | 4.13% | +10.08% |
| Vanguardindex-like | $286.9M | 3.80% | +7.50% |
| State Streetindex-like | $269.5M | 3.57% | +22.98% |
Bull1
Bear2